NIH Extramural Funding: The Rich Get Richer

Dollar Amount By 1987, the elite group of 10 institutions was still getting its outsized share—19% of the extramural awards—but the dollar amount had more than doubled to $996 million. Membership in the top of 10 has not shifted significantly during the past decade. Of those institutions at the top in 1978, only one had dropped out by 1987. Moving down the list of NIH recipents for 1987, the top 100 institutions as a whole received a little more than three-quarters of the whol

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

By 1987, the elite group of 10 institutions was still getting its outsized share—19% of the extramural awards—but the dollar amount had more than doubled to $996 million.

Membership in the top of 10 has not shifted significantly during the past decade. Of those institutions at the top in 1978, only one had dropped out by 1987.

Moving down the list of NIH recipents for 1987, the top 100 institutions as a whole received a little more than three-quarters of the whole budget. That left only a quarter to be divided among the remaining 1,436 institutions.

This concentration of funds is appropriate, according to John Lein, vice president for health sciences at the University of Washington. He argues that for the United States to compete internationally with only modest money for science, it’s best to give those funds to institutions with the best chance of making a difference. “You need ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies